The trial will also evaluate patients with diffuse large B-cell lymphoma, peripheral T-cell lymphoma and other less common lymphoma subtypes.
The trial will investigate the antitumor activity, duration of response and safety profile of Adcetris in these patients.
The company expects to recruit around 55 patients in various centers across the US.
Seattle Genetics chief medical officer Thomas Reynolds said this clinical trial is part of their comprehensive development plan to evaluate the potential of Adcetris in CD30-positive malignancies, building on the data they have generated in certain patients with Hodgkin lymphoma and systemic ALCL.
"We believe the targeting ability of Adcetris to CD30 provides opportunities in selected lymphoma subtypes," Reynolds said.